Does Tymlos (abaloparatide) cause tachycardia as a side effect?

Does Tymlos Cause Rapid Heart Rate?

Yes, Tymlos (abaloparatide) does cause tachycardia as a documented side effect, with adverse reactions of tachycardia (including sinus tachycardia) reported in 2% of patients receiving the medication compared to 1% in placebo groups. 1

Cardiovascular Effects of Tymlos

Heart Rate Increases

• Tymlos causes a dose-dependent increase in heart rate that develops within 15 minutes after injection and typically resolves within approximately 6 hours. 1

• In clinical trials, the mean heart rate change from pretreatment to 1 hour post-treatment was 7.9 beats per minute (bpm) for abaloparatide, compared to 1.2 bpm for placebo. 2

• Among the 13 patients receiving Tymlos who experienced tachycardia, symptoms occurred within 1 hour of administration in 5 patients. 1

• In healthy volunteers, the heart rate increase resolved within 4 hours of administration. 2

Palpitations

• Palpitations were reported in 5% of Tymlos-treated patients versus 0.4% in placebo groups, making this one of the most common adverse reactions leading to study drug discontinuation (1% of patients). 1

• Palpitations and increased heart rate represent a somewhat higher occurrence of adverse effects with abaloparatide compared to teriparatide, contributing to treatment discontinuation. 3, 4

Blood Pressure Effects

• Tymlos causes small decreases in blood pressure alongside the heart rate increases. 2

• The mean change in supine systolic and diastolic blood pressure 1 hour post-treatment was -2.7/-3.6 mmHg for abaloparatide, compared to -1.5/-2.3 mmHg for placebo. 2

• Orthostatic hypotension was reported in 1% of Tymlos-treated patients versus 0.5% receiving placebo. 1

• The incidence of orthostatic blood pressure decline ≥20 mmHg systolic or ≥10 mmHg diastolic at 1 hour after the first injection was 4% in the Tymlos group and 3% in the placebo group. 1

Overall Cardiovascular Safety Profile

• Despite the transient increases in heart rate, there was no increase in risk of serious cardiac adverse events, major adverse cardiovascular events (MACE), or heart failure with Tymlos. 2

• The percentage of participants with serious cardiac adverse events was similar among all treatment groups (0.9%-1.0%). 2

• In a post hoc analysis, time to first incidence of MACE plus heart failure was actually longer with abaloparatide compared to placebo (P = 0.02). 2

Clinical Implications

Common Cardiovascular Side Effects

The most frequently reported cardiovascular-related adverse reactions include:

• Palpitations: 5% (vs 0.4% placebo) 1
• Dizziness: 10% (vs 6% placebo) 1
• Tachycardia: 2% (vs 1% placebo) 1

Discontinuation Rates

• Overall, 10% of Tymlos-treated patients discontinued due to adverse events compared to 6% in the placebo group. 1

• The most common adverse reactions leading to discontinuation were nausea (2%), dizziness (1%), headache (1%), and palpitations (1%). 1

Patient Counseling

• Patients should be informed that heart rate increases are transient, typically developing within 15 minutes and resolving within 4-6 hours after injection. 1, 2

• The cardiovascular effects are generally mild and self-limiting, with no evidence of increased serious cardiac complications. 2

• Patients experiencing persistent or concerning palpitations or tachycardia should be evaluated, though these symptoms do not indicate increased cardiovascular risk based on clinical trial data. 2